Biological and Medicinal Chemistry

Identification and Semisynthesis of (–)-Anisomelic Acid as an Oral Antiviral Agent against SARS-CoV-2 in Mice

Authors

Abstract

(–)-Anisomelic acid (AA), isolated from Anisomeles indica (L.) Kuntze (Labiatae) leaves, is a macrocyclic cembranolide with a trans-fused α-methylene-β-lactone motif. Cytopathic effect assays showed that the anti-SARS-CoV-2 effect of AA (IC50 = 4.3 μM) is comparable to that of remdesivir (IC50 = 2.1 μM), and more potent than that of molnupiravir (IC50 = 27.8 μM). Challenge studies in SARS-CoV-2-infected K18-hACE2 mice showed that orally administration of AA and remdesivir can both reduce the viral titers in the lung tissue at the same level. To facilitate drug discovery, we used a semisynthetic approach to shorten the project timelines. The enantioselective semisynthesis of AA from the naturally enriched and commercially available starting material (+)-costunolide was achieved in five steps with a 27% overall yield. The developed chemistry provides opportunities for developing AA-based novel ligands for selectively targeting proteins involved in viral infection.

Content

Thumbnail image of ChemRxiv Submission MS Add In Mice.pdf

Supplementary material

Thumbnail image of ChemRxiv Submission SI in Mice.pdf
Supplementary Materials
This document contains the supplementary materials for <Identification and Semi-synthesis of (−)-Anisomelic Acid as an Oral Antiviral Agent against SARS-CoV-2>, including in vitro antiviral activity assays, in vivo antiviral activity assays, materials and methods, Figs. S1 to S3, spectral data, single-crystal XRD data and references.